Literature DB >> 19925639

Insider access: pepducin symposium explores a new approach to GPCR modulation.

Jacquelyn Miller1, Anika Agarwal, Lakshmi A Devi, Kellen Fontanini, James A Hamilton, Jean-Philippe Pin, Denis C Shields, C Arnold Spek, Thomas P Sakmar, Athan Kuliopulos, Stephen W Hunt.   

Abstract

The inaugural Pepducin Science Symposium convened in Cambridge, Massachusetts on March 8-9, 2009 provided the opportunity for an international group of distinguished scientists to present and discuss research regarding G protein-coupled receptor-related research. G protein-coupled receptors (GPCRs) are, arguably, one of the most important molecular targets in drug discovery and pharmaceutical development today. This superfamily of membrane receptors is central to nearly every signaling pathway in the human body and has been the focus of intense research for decades. However, as scientists discover additional properties of GPCRs, it has become clear that much is yet to be understood about how these receptors function. Everyone agrees, however, that tremendous potential remains if specific GPCR signaling pathways can be modulated to correct pathological states. One exciting new approach to this challenge involves pepducins: novel, synthetic lipopeptide pharmacophores that modulate heptahelical GPCR activity from inside the cell membrane.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19925639     DOI: 10.1111/j.1749-6632.2009.05326.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

1.  Biological activity in vitro and in vivo of peptides corresponding to the third intracellular loop of thyrotropin receptor.

Authors:  E A Shpakova; A O Shpakov; O V Chistyakova; I V Moyseyuk; K V Derkach
Journal:  Dokl Biochem Biophys       Date:  2012-05-05       Impact factor: 0.788

2.  Biological activity of lipophilic derivatives of peptide 562-572 of rat luteinizing hormone receptor.

Authors:  E A Shpakova; K V Derkach; A O Shpakov
Journal:  Dokl Biochem Biophys       Date:  2013-10-23       Impact factor: 0.788

Review 3.  [Novel achievements in development and application of GPCR-peptides].

Authors:  A O Shpakov; K V Derkach
Journal:  Zh Evol Biokhim Fiziol       Date:  2015 Jan-Feb

Review 4.  Neutrophil Signaling That Challenges Dogmata of G Protein-Coupled Receptor Regulated Functions.

Authors:  Claes Dahlgren; André Holdfeldt; Simon Lind; Jonas Mårtensson; Michael Gabl; Lena Björkman; Martina Sundqvist; Huamei Forsman
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-11

Review 5.  The cytoplasmic rhodopsin-protein interface: potential for drug discovery.

Authors:  Naveena Yanamala; Eric Gardner; Alec Riciutti; Judith Klein-Seetharaman
Journal:  Curr Drug Targets       Date:  2012-01       Impact factor: 3.465

6.  Full characterization of GPCR monomer-dimer dynamic equilibrium by single molecule imaging.

Authors:  Rinshi S Kasai; Kenichi G N Suzuki; Eric R Prossnitz; Ikuko Koyama-Honda; Chieko Nakada; Takahiro K Fujiwara; Akihiro Kusumi
Journal:  J Cell Biol       Date:  2011-02-07       Impact factor: 10.539

7.  Signal protein-derived peptides as functional probes and regulators of intracellular signaling.

Authors:  Alexander O Shpakov
Journal:  J Amino Acids       Date:  2011-08-23

8.  Formyl peptide derived lipopeptides disclose differences between the receptors in mouse and men and call the pepducin concept in question.

Authors:  Malene Winther; André Holdfeldt; Martina Sundqvist; Zahra Rajabkhani; Michael Gabl; Johan Bylund; Claes Dahlgren; Huamei Forsman
Journal:  PLoS One       Date:  2017-09-21       Impact factor: 3.240

Review 9.  Protease-Activated Receptor 1 as Therapeutic Target in Breast, Lung, and Ovarian Cancer: Pepducin Approach.

Authors:  Lidija Covic; Athan Kuliopulos
Journal:  Int J Mol Sci       Date:  2018-07-31       Impact factor: 5.923

Review 10.  The Formyl Peptide Receptors: Diversity of Ligands and Mechanism for Recognition.

Authors:  Hui-Qiong He; Richard D Ye
Journal:  Molecules       Date:  2017-03-13       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.